side effects of semaglutide and tirzepatide caused roughly half as many patients to stop treatment because gastrointestinal as semaglutide. In the first major head-to-head obesity trial, GI side effects caused treatment discontinuation in: Tirzepatide Tirzepatide caused roughly half as

Bailey Bryan is a healthcare communications specialist at Call-On-Doc with over three years of experience helping patients access reliable, high-quality care

When you stop the medication, these signals gradually normalize over weeks to months, often causing appetite to surge back to pre-treatment levels

However, its important to approach it as part of a comprehensive weight loss strategy that includes lifestyle changes

Its essential for normal body function and development in every man

BPC 157 promotes gastrointestinal tract healing and protects against lesions, maintaining the integrity of the stomach lining and other tissues

The PIONEER 4 trial demonstrated oral semaglutide at 14 mg produced approximately 9.6% weight loss, while SUSTAIN 10 showed injectable semaglutide at 2.4 mg achieved 12.3% weight loss over comparable 68-week periods in similar populations